ArticleThe journal of allergy and clinical immunology. In practice2023
Blood Eosinophils for Prediction of Exacerbation in Preschool Children With Recurrent Wheezing.
Article in The journal of allergy and clinical immunology. In practice, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 27 citations in OpenAlex.
- Real-world chest radiograph findings and clinical consequences in preschool children with recurrent wheezing.BMC pediatrics · 2026Article
- Review
- Preschool wheeze endotypes and their association with asthma attacks and inhaled corticosteroid response.ERJ open research · 2026Article
- Understanding recurrent wheezing: A parent's guide.World journal of clinical pediatrics · 2026Article
- An expert opinion on the management of pediatric patients with wheezing and mild asthma: translating 2025 GINA strategy report into clinical practice in Italy.Italian journal of pediatrics · 2026Review
- Construction and validation of a predictive model for recurrent wheezing risk within one year after initial hospitalization for RSV lower respiratory tract infection in preschool children.Frontiers in pediatrics · 2026Article
- Integrative analysis of vitamin D, ferritin, and eosinophilic inflammation in predicting acute exacerbations of childhood asthma.Frontiers in immunology · 2026Article
- Risk Factors and Mechanisms Leading to Preschool Recurrent Wheeze and Asthma.The journal of allergy and clinical immunology. In practice · 2025Review
- Using mHealth to Predict Asthma Exacerbations in Children and Adolescents (Mobile Health for Kids With Asthma): Protocol for an Observational Study.JMIR research protocols · 2025Article
- Article
- ERS Congress 2024: highlights from the Paediatrics Assembly.ERJ open research · 2025Article
- Predicting exacerbations in severe preschool wheezers.Pediatric pulmonology · 2025Review
- Early risk identification for recurrent wheezing in children with respiratory syncytial virus infections.American journal of translational research · 2025Article
- Plasma metabolomics identifies differing endotypes of recurrent wheezing in preschool children differentiated by symptoms and social disadvantage.Scientific reports · 2024Article
- Association between advanced lung cancer inflammation index and unstable asthma: a population-based study from the NHANES 2007-2018.Frontiers in nutrition · 2024Article
- Review
- Real-world phenotyping and risk assessment of childhood asthma burden using national registries.Respiratory medicineArticle
Corrections and comments
- Commented on by
- Commented on by
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
Abstract
backgroundAlthough clinical features of type 2 inflammation have been associated with poorer longitudinal outcomes in preschool children with recurrent wheezing, it remains difficult to predict which children are at highest risk for poor outcomes during a routine clinical encounter.
objectiveWe tested the hypothesis that prespecified cut points of blood eosinophil counts would predict exacerbation and treatment response outcomes in preschool children with recurrent wheezing and that prediction could be improved with the addition of a second biomarker.
methodsData from 3 clinical trials of 1,074 preschool children aged 12 to 71 months with recurrent wheezing were merged. The primary outcome was the occurrence of any exacerbation during follow-up. Secondary outcomes included the annualized rate of wheezing exacerbations and the occurrence of any exacerbation requiring hospitalization. Exploratory analyses focused on exacerbation outcomes, offline exhaled nitric oxide concentrations, and caregiver-reported asthma control scores after inhaled corticosteroid treatment initiation.
resultsEach blood eosinophil cut point was associated with increased odds of exacerbation, higher exacerbation rates, and greater hospitalization occurrence in preschool children with recurrent wheezing. However, outcome detection was improved in children with more elevated blood eosinophil counts. Addition of a second biomarker of type 2 inflammation improved outcome detection and was further associated with an improved response to initiation of daily inhaled corticosteroids in exploratory analyses. However, the specificity of blood eosinophils was poor.
conclusionsAlthough validation studies are warranted, blood eosinophil cut points may be useful for clinical assessment and future studies of exacerbation and treatment response in preschool children with recurrent wheezing.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.